Background—Adjunctive unfractionated heparin (UFH) during thrombolytic therapy for acute myocardial infarction (AMI) promotes the speed and magnitude of coronary artery recanalization and reduces reocclusion. Low-molecular-weight heparins offer practical and potential pharmacological advantages over UFH in multiple applications but have not been systematically studied as adjuncts to fibrinolysis in AMI. Methods and Results—Four hundred patients undergoing reperfusion therapy with an accelerated recombinant tissue plasminogen activator regimen and aspirin for AMI were randomly assigned to receive adjunctive therapy for at least 3 days with either enoxaparin or UFH. The study was designed to show noninferiority of enoxaparin versus UFH with r...
BACKGROUND: The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may fa...
BACKGROUND: Whether low-molecular-weight heparin (LMWH) is superior to unfractionated heparin (UFH) ...
Background—Current pharmacotherapeutic options for high-risk non–ST-segment elevation acute coronary...
Background: Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients...
Background: Despite the overwhelming progress that has been accomplished in the prevention of mortal...
Background—Low-molecular-weight heparins are attractive alternatives to unfractionated heparin (UFH)...
Background: Most patients with acute myocardial infarction with ST-segment elevation (STEMI) are sti...
ObjectivesWe sought to evaluate whether enoxaparin (ENOX) is superior to unfractionated heparin (UFH...
Objectives We sought to evaluate whether enoxaparin (ENOX) is superior to unfractionated heparin (UF...
Background: Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low...
ObjectivesThe purpose of this study was to determine the efficacy and safety of enoxaparin (ENOX) ve...
SummaryBackgroundWhether low molecular weight heparin (LMWH) enoxaparin is equivalent to unfractiona...
Background: Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agen...
Andrea Rubboli1, Alessandro Capecchi2, Giuseppe Di Pasquale11Division of Cardiology, Maggiore Hospit...
AbstractA substantial number of clinical studies have consistently demonstrated that low-molecular-w...
BACKGROUND: The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may fa...
BACKGROUND: Whether low-molecular-weight heparin (LMWH) is superior to unfractionated heparin (UFH) ...
Background—Current pharmacotherapeutic options for high-risk non–ST-segment elevation acute coronary...
Background: Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients...
Background: Despite the overwhelming progress that has been accomplished in the prevention of mortal...
Background—Low-molecular-weight heparins are attractive alternatives to unfractionated heparin (UFH)...
Background: Most patients with acute myocardial infarction with ST-segment elevation (STEMI) are sti...
ObjectivesWe sought to evaluate whether enoxaparin (ENOX) is superior to unfractionated heparin (UFH...
Objectives We sought to evaluate whether enoxaparin (ENOX) is superior to unfractionated heparin (UF...
Background: Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low...
ObjectivesThe purpose of this study was to determine the efficacy and safety of enoxaparin (ENOX) ve...
SummaryBackgroundWhether low molecular weight heparin (LMWH) enoxaparin is equivalent to unfractiona...
Background: Enoxaparin was superior to unfractionated heparin (UFH), regardless of fibrinolytic agen...
Andrea Rubboli1, Alessandro Capecchi2, Giuseppe Di Pasquale11Division of Cardiology, Maggiore Hospit...
AbstractA substantial number of clinical studies have consistently demonstrated that low-molecular-w...
BACKGROUND: The combination of a single-bolus fibrinolytic and a low-molecular-weight heparin may fa...
BACKGROUND: Whether low-molecular-weight heparin (LMWH) is superior to unfractionated heparin (UFH) ...
Background—Current pharmacotherapeutic options for high-risk non–ST-segment elevation acute coronary...